However, driven by shifts in dietary patterns and rising obesity rates, its incidence and prevalence are steadily increasing, with the disease increasingly manifesting in younger individuals ( Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a novel class of antidiabetic agents that activate the GLP-1 receptor to stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner, delay gastric emptying, thereby controlling blood glucose and promoting weight loss ( Previous meta-analyses have primarily pooled the cardiovascular effects of GLP-1 RAs in patients with T2DM ( This study performed a systematic review and meta-analysis to evaluate the effects of subcutaneous vs
A dual GIP/GLP-1 receptor agonist, used in incretin-pathway metabolic research
Estos frmacos retrasan el vaciamiento gstrico y modifican la motilidad intestinal, lo que puede alterar los patrones de evacuacin
Do not stop prescribed medicines or supplements without professional guidance
GLP-1 medicines have changed what is possible in obesity and type 2 diabetes, but they require chronic, high-dose systemic exposure that many patients cannot or do not sustain, said Harith Rajagopalan, MD, PhD, co-founder and CEO of Fractyl Health
What is the difference between orforglipron and tirzepatide
